bismuth has been researched along with Lymphoma, Non-Hodgkin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, SJ; Choi, J; Chung, H; Chung, SJ; Kim, JL; Kim, SG; Lee, A | 1 |
| Friesen, C; Hormann, I; Leib, O; Marx, S; Miltner, E; Moreno, J; Roscher, M | 1 |
| Axtman, A; Bäck, T; Fisher, DR; Frayo, S; Gopal, AK; Green, DJ; Hamlin, DK; Kenoyer, AL; Lin, Y; Orgun, N; Pagel, JM; Park, SI; Press, OW; Shenoi, J; Wilbur, DS | 1 |
| Marshall, BJ | 1 |
1 review(s) available for bismuth and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
[Management of the peptic ulcer patient in the Helicobacter pylori age].
Topics: Algorithms; Antacids; Anti-Bacterial Agents; Biopsy; Bismuth; Breath Tests; Child; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Immunologic Techniques; Lymphoma, Non-Hodgkin; Metronidazole; Peptic Ulcer; Stomach Neoplasms | 1994 |
1 trial(s) available for bismuth and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, Non-Hodgkin; Male; Metronidazole; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Republic of Korea; RNA, Ribosomal, 23S; Stomach Neoplasms; Tetracycline; Treatment Outcome | 2020 |
2 other study(ies) available for bismuth and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells.
Topics: Alpha Particles; Antigens, CD20; Apoptosis; Bismuth; Caspases; Cell Cycle; Down-Regulation; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Immunotoxins; Lymphoma, Non-Hodgkin; Radiation Tolerance; Radioimmunotherapy; Radioisotopes; Signal Transduction | 2013 |
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
Topics: Animals; Antibodies, Neoplasm; Antigens, CD20; Biotin; Bismuth; Blood Cell Count; Cell Line, Tumor; Humans; Immunoglobulin Variable Region; Kidney; Liver Function Tests; Lymphoma, Non-Hodgkin; Mice; Neoplasm, Residual; Organometallic Compounds; Radioimmunotherapy; Radiometry; Recombinant Fusion Proteins; Survival Analysis; Tissue Distribution; Xenograft Model Antitumor Assays | 2010 |